Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04907539
Title A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Redx Pharma Plc
Indications

colorectal cancer

Therapies

Denosumab + Nivolumab + RXC004

Denosumab + RXC004

Age Groups: adult | senior
Covered Countries USA | ESP


No variant requirements are available.